NCT00293267View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

PHASE3CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

May 31, 2011

Conditions
HIV Infections
Interventions
DRUG

raltegravir potassium

Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.

DRUG

Comparator: Placebo

Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00293267 - A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2) | Biotech Hunter | Biotech Hunter